Leukemogenic risk prediction of the cytostatic treatment
Raposa, T.; Varkonyi, J.
Progress in Clinical and Biological Research 340d: 53-63
1990
ISSN/ISBN: 0361-7742 PMID: 2196584 Document Number: 358044
Document emailed within 1 workday
Related Documents
Al-Jam'a, A.H.; Al-Dabbous, I.A.; Al-Khatti, A.A.; Esan, F.G. 2002: Are we underestimating the leukemogenic risk of hydroxyurea Saudi Medical Journal 23(11): 1411-1413Nilsson, A.; Björk, O. 2001: A mannose-binding blood protein reduces the risk of infections drug treatment with cytostatic agents Lakartidningen 98(50): 5780
Bolsin, S.N. 1997: Risk prediction in coronary artery surgery: a comparison of four risk scores Medical Journal of Australia 167(7): 397; 400
Hang, D.; Shen, H.B. 2019: Application of polygenic risk scores in risk prediction and precision prevention of complex diseases: opportunities and challenges Zhonghua Liu Xing Bing Xue Za Zhi 40(9): 1027-1030
Günther, I.; Gladitz, G. 1972: Cytostatic treatment of plasmacytoma Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 27(21): 933-937
Savill, P. 2009: QDScore: a risk prediction tool for diabetes Practitioner 253(1717): 5
Yoshida, T.; Hara, N.; Furukawa, T.; Inokuchi, K. 1982: Prediction of the risk of pulmonary complication after surgery Nihon Kyobu Geka Gakkai 30(11): 1779-1783
Sattar, N.; Welsh, P.; Sarwar, N.; Danesh, J.; Di Angelantonio, E.; Gudnason, V.; Davey Smith, G.; Ebrahim, S.; Lawlor, D.A. 2010: NT-proBNP is associated with coronary heart disease risk in healthy older women but fails to enhance prediction beyond established risk factors: results from the British Women's Heart and Health Study Atherosclerosis 209(1): 295-299
Neijt, J.P. 1999: Cytostatic treatment of ovarian carcinoma Nederlands Tijdschrift Voor Geneeskunde 143(44): 2181-2185
Winter, S.T.; Lilos, P. 1974: Prediction of hospitalization during infancy: scoring the risk of admission Pediatrics 53(5): 716-720
Zodpey, S.P.; Tiwari, R.R. 2005: A risk scoring system for prediction of haemorrhagic stroke Indian Journal of Public Health 49(4): 218-222
Klener, P. 1981: Hematopoietic disorders resulting from cytostatic treatment Casopis Lekaru Ceskych 120(25): 769-773
Morgenstern, D.; Fleischer, J. 1974: Changes in the lung in lymphogranulomatosis and the results of cytostatic treatment Folia Haematologica 101(4): 588-593
Steineck, G.; Wijkström, H.; Borghede, G. 1994: Treatment of bladder cancer with cytostatic agents Lakartidningen 91(5): 397-404
Moe, P.J. 1970: Cytostatic treatment of malignant disease in children Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 90(11): 1196-1201
Petru, E.; Benedicic, C.; Seewann, A.; Pickel, H. 2003: Palliative cytostatic treatment of cervical carcinoma European Journal of Gynaecological Oncology 24(6): 473-474
Halvorsen, S. 1971: Cytostatic agents in treatment of the nephrotic syndrome Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 91(10): 737
Wisløff, F.; Brinch, L.; Bruserud, O.; Dahl, I.M.; Lamvik, J. 1994: Treatment with high-dose cytostatic agents Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 114(26): 3115-3116
Chlund, K. 1970: Treatment of ulcerative colitis with cytostatic agents Wiener Medizinische Wochenschrift 120(16): 274
Rauh, J.; Pluntke, S.; Müller, C. 2004: Treatment of perivascular extravasation of cytostatic agents MMW Fortschritte der Medizin 146(31-32): 23-24; 26-27